Activity and Interactions of Liposomal Antibiotics in Presence of Activity and Interactions of Liposomal Antibiotics in Presence of Polyanions and Sputum of Patients with Cystic Fibrosis Polyanions and Sputum of Patients with Cystic Fibrosis

Background: To compare the effectiveness of liposomal tobramycin or polymyxin B against Pseudomonas aeruginosa in the Cystic Fibrosis (CF) sputum and its inhibition by common polyanionic components such as DNA, F-actin, lipopolysaccharides (LPS), and lipoteichoic acid (LTA). Methodology: Liposomal formulations were prepared from a mixture of 1,2-Dimyristoyl-sn -Glycero-3-Phosphocholine (DMPC) or 1,2-Dipalmitoyl-sn -Glycero-3-Phosphocholine (DPPC) and Cholesterol (Chol), respectively. Stability of the formulations in different biological milieus and antibacterial activities compared to conventional forms in the presence of the aforementioned inhibitory factors or CF sputum were evaluated. Results: The formulations were stable in all conditions tested with no significant differences compared to the controls. Inhibition of antibiotic formulations by DNA/F-actin and LPS/LTA was concentration dependent. DNA/F-actin (125 to 1000 mg/L) and LPS/LTA (1 to 1000 mg/L) inhibited conventional tobramycin bioactivity, whereas, liposome-entrapped tobramycin was inhibited at higher concentrations - DNA/F-actin (500 to 1000 mg/L) and LPS/LTA (100 to 1000 mg/L). Neither polymyxin B formulation was inactivated by DNA/F-actin, but LPS/LTA (1 to 1000 mg/L) inhibited the drug in conventional form completely and higher concentrations of the inhibitors (100 to 1000 mg/L) was required to inhibit the liposome-entrapped polymyxin B. Co-incubation with inhibitory factors (1000 mg/L) increased conventional (16-fold) and liposomal (4-fold) tobramycin minimum bactericidal concentrations (MBCs), while both polymyxin B formulations were inhibited 64-fold. Conclusions: Liposome-entrapment reduced antibiotic inhibition up to 100-fold and the CFU of endogenous P. aeruginosa in sputum by 4-fold compared to the conventional antibiotic, suggesting their potential applications in CF lung infections.

[1]  M. Wildman,et al.  Duration of intravenous antibiotic therapy in people with cystic fibrosis. , 2016, The Cochrane database of systematic reviews.

[2]  T. Remmington,et al.  Oral anti-pseudomonal antibiotics for cystic fibrosis. , 2016, The Cochrane database of systematic reviews.

[3]  Abdelwahab Omri,et al.  Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. , 2008, International journal of pharmaceutics.

[4]  G. James,et al.  Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. , 2008, The Journal of antimicrobial chemotherapy.

[5]  T. Ferkol,et al.  Airway inflammation in cystic fibrosis. , 2008, Chest.

[6]  Jian Li,et al.  Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. , 2007, The Journal of antimicrobial chemotherapy.

[7]  James R. Smith,et al.  Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. , 2007, Pulmonary pharmacology & therapeutics.

[8]  J. Iredell.  Optimizing antipseudomonal therapy in critical care. , 2007, Seminars in respiratory and critical care medicine.

[9]  M. Boyle.  Adult cystic fibrosis. , 2007, JAMA.

[10]  S. M. Kirov,et al.  Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. , 2007, Microbiology.

[11]  Aseem Kumar,et al.  Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. , 2007, The Journal of antimicrobial chemotherapy.

[12]  A. Knox,et al.  Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[13]  B. Rubin,et al.  The Role of DNA and Actin Polymers on the Polymer Structure and Rheology of Cystic Fibrosis Sputum and Depolymerization by Gelsolin or Thymosin Beta 4 , 2007, Annals of the New York Academy of Sciences.

[14]  P. Janmey,et al.  Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. , 2007, The Journal of antimicrobial chemotherapy.

[15]  M. Son,et al.  In Vivo Evidence of Pseudomonas aeruginosa Nutrient Acquisition and Pathogenesis in the Lungs of Cystic Fibrosis Patients , 2007, Infection and Immunity.

[16]  S. Kharitonov,et al.  Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. , 2007, Contributions to microbiology.

[17]  M. Konstan,et al.  Sputum biomarkers of inflammation in cystic fibrosis lung disease. , 2007, Proceedings of the American Thoracic Society.

[18]  H. Frijlink,et al.  Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[19]  T. Lahiri.  Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis. , 2007, Clinics in chest medicine.

[20]  B. Rubin,et al.  Emerging and unusual gram-negative infections in cystic fibrosis. , 2007, Seminars in respiratory and critical care medicine.

[21]  T. Hermann,et al.  Aminoglycoside antibiotics: old drugs and new therapeutic approaches , 2007, Cellular and Molecular Life Sciences.

[22]  P. Janmey,et al.  Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum , 2007, European Respiratory Journal.

[23]  M. Konstan,et al.  Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety , 2007, Pediatric pulmonology.

[24]  T. Murray,et al.  Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients , 2007, Current opinion in pediatrics.

[25]  S. Wilkinson,et al.  Acute renal failure associated with inhaled tobramycin. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[26]  M. R. Mozafari,et al.  Recent trends in the lipid-based nanoencapsulation of antioxidants and their role in foods , 2006 .

[27]  O. Holst,et al.  Alanine Esters of Enterococcal Lipoteichoic Acid Play a Role in Biofilm Formation and Resistance to Antimicrobial Peptides , 2006, Infection and Immunity.

[28]  Abdelwahab Omri,et al.  Mechanism of Enhanced Activity of Liposome-Entrapped Aminoglycosides against Resistant Strains of Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.

[29]  Abdelwahab Omri,et al.  Preparation and characterization of dehydration-rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. , 2006, International journal of pharmaceutics.

[30]  J. Hupp,et al.  Mucin–Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance , 2006, Molecular microbiology.

[31]  C. Goss,et al.  Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. , 2005, Chest.

[32]  Jay X. Tang,et al.  Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[33]  M. Falagas,et al.  Effect of Aerosolized Colistin on Multidrug-Resistant Pseudomonas aeruginosa in Bronchial Secretions of Patients without Cystic Fibrosis , 2005, Journal of chemotherapy.

[34]  K. Malcolm,et al.  Enhanced Pseudomonas aeruginosa Biofilm Development Mediated by Human Neutrophils , 2005, Infection and Immunity.

[35]  Matthew E Falagas,et al.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  J. Elborn,et al.  Cytokines and inflammatory mediators in cystic fibrosis. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[37]  N. McElvaney,et al.  Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. , 2004, The Journal of infectious diseases.

[38]  S. Hammer,et al.  Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. , 2004, The Journal of antimicrobial chemotherapy.

[39]  P. Janmey,et al.  The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. , 2003, American journal of respiratory cell and molecular biology.

[40]  P. Shek,et al.  Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. , 2002, Biochemical pharmacology.

[41]  M. Hodson,et al.  A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis , 2002, European Respiratory Journal.

[42]  J. Govan.  TOBI: reducing the impact of pseudomonal infection. , 2002, Hospital medicine.

[43]  S. D. De Smedt,et al.  On the Transport of Lipoplexes Through Cystic Fibrosis Sputum , 2002, Pharmaceutical Research.

[44]  R. Hancock,et al.  Cationic peptides: effectors in innate immunity and novel antimicrobials. , 2001, The Lancet. Infectious diseases.

[45]  R. Schiffelers,et al.  Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. , 2001, The Journal of antimicrobial chemotherapy.

[46]  S. Smedt,et al.  Structural alterations of gene complexes by cystic fibrosis sputum. , 2001, American journal of respiratory and critical care medicine.

[47]  S. Smedt,et al.  Cystic fibrosis sputum: a barrier to the transport of nanospheres. , 2000, American journal of respiratory and critical care medicine.

[48]  R. Hancock,et al.  PhoP–PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer‐membrane protein OprH and polymyxin B resistance , 1999, Molecular microbiology.

[49]  H. Ceri,et al.  The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms , 1999, Journal of Clinical Microbiology.

[50]  M. Pepe,et al.  A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. , 1997, Chest.

[51]  B. Ramsey,et al.  Macromolecular mechanisms of sputum inhibition of tobramycin activity , 1995, Antimicrobial agents and chemotherapy.

[52]  L. Piddock,et al.  Interaction of divalent cations, quinolones and bacteria. , 1994, The Journal of antimicrobial chemotherapy.

[53]  P. Janmey,et al.  Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. , 1994, Science.

[54]  J. Lafitte,et al.  The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases. , 1992, The Journal of antimicrobial chemotherapy.

[55]  R. Fielding.  Liposomal Drug Delivery , 1991, Clinical pharmacokinetics.

[56]  M. Lethem,et al.  The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. , 1990, The European respiratory journal.

[57]  R. Ramphal,et al.  The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. , 1988, The Journal of antimicrobial chemotherapy.

[58]  B. Ramsey,et al.  Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. , 1983, The Journal of infectious diseases.

[59]  R. Hancock,et al.  Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin , 1980, Journal of bacteriology.

[60]  N. Tanaka,et al.  Interaction of aminoglycosides and other antibiotics with actin. , 1979, The Journal of antibiotics.

[61]  M. Davies,et al.  The binding of lipopolysaccharide from Escherichia coli to mammalian cell membranes and its effect on liposomes. , 1978, Biochimica et biophysica acta.

[62]  J. L. Potter,et al.  Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions. , 1965, Pediatrics.

[63]  M. Kollef,et al.  The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections , 2012, Drugs.

[64]  M. R. Mozafari,et al.  Nanoliposomes and their applications in food nanotechnology. , 2008, Journal of liposome research.

[65]  A. Chuchalin,et al.  A Formulation of Aerosolized Tobramycin (Bramitob®) in the Treatment of Patients with Cystic Fibrosis and Pseudomonas aeruginosa Infection , 2007, Paediatric drugs.

[66]  G. Lenoir,et al.  Efficacy, Safety, and Local Pharmacokinetics of Highly Concentrated Nebulized Tobramycin in Patients with Cystic Fibrosis Colonized with Pseudomonas aeruginosa , 2007, Paediatric drugs.

[67]  D. Kaye.  Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides. , 2004, Infectious disease clinics of North America.

[68]  E. Alton,et al.  The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro , 1998, Gene Therapy.

[69]  G. Kaloyanides,et al.  Aminoglycoside nephrotoxicity. , 1980, Kidney international.

[70]  W. T. Bruns,et al.  Effects of sputum from patients with cystic fibrosis on the activity in vitro of 5 antimicrobial drugs on Pseudomonas aeruginosa. , 1978, The American review of respiratory disease.